TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03725384

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous Sulfate 300Mg Tablet
Description: oral dose of Ferrous Sulfate (300 mg) every day versus every other day along with vitamin C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferrous Sulfate 300Mg Tablet
Description: oral dose of Ferrous Sulfate (300 mg) every day versus every other day along with vitamin C

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C 500Mg tablet
Description: Vitamin C 500 Mg tablet every day versus every other day along with ferrous sulfate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C 500Mg tablet
Description: Vitamin C 500 Mg tablet every day versus every other day along with ferrous sulfate
Study: NCT02369913

Intervention type: OTHER
Intervention: Blood Drawn
Description: Both groups will have 1 teaspoon of blood drawn for analysis.

Intervention type: OTHER
Intervention: Blood Drawn
Description: Both groups will have 1 teaspoon of blood drawn for analysis.
Study: NCT02733445

Intervention type: DRUG
Intervention: dasatinib

Intervention type: DRUG
Intervention: nilotinib
Study: NCT01553019

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton radiation
Description: Proton Radiation Therapy: R(0) negative ... 50.40 cobalt gray equivalent (CGE) at 1.8 CGE per fraction ; R(1) micro-positive ...54.00 CGE at 1.8 CGE per fraction; R(2) gross positive...59.40 CGE at 1.8 CGE per fraction

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton radiation
Description: Proton Radiation Therapy: R(0) negative ... 50.40 cobalt gray equivalent (CGE) at 1.8 CGE per fraction ; R(1) micro-positive ...54.00 CGE at 1.8 CGE per fraction; R(2) gross positive...59.40 CGE at 1.8 CGE per fraction

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton radiation
Description: Proton Radiation Therapy: R(0) negative ... 50.40 cobalt gray equivalent (CGE) at 1.8 CGE per fraction ; R(1) micro-positive ...54.00 CGE at 1.8 CGE per fraction; R(2) gross positive...59.40 CGE at 1.8 CGE per fraction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 300 mg/m2 infused over 30 minutes, weekly during proton therapy.
Study: NCT02804815

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 100mg
Description: Aspirin 100mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 300mg
Description: Aspirin 300mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 100mg
Description: Placebo 100mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 300mg
Description: Placebo 300mg
Study: NCT01553019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 300 mg/m2 infused over 30 minutes, weekly during proton therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 300 mg/m2 infused over 30 minutes, weekly during proton therapy.
Study: NCT04531241

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACUVUE® OASYS 1-DAY
Description: senofilcon A contact lenses made with a novel manufacturing technology

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACUVUE® OASYS 1-DAY
Description: senofilcon A contact lenses made with a novel manufacturing technology

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACUVUE® OASYS 1-DAY
Description: senofilcon A contact lenses made with the current manufacturing technology

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACUVUE® OASYS 1-DAY
Description: senofilcon A contact lenses made with the current manufacturing technology
Study: NCT01603589

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary artery bypass grafting with the use of minimal invasive extracorporeal circulation
Description: We use a prototype AHEPA (modular type IV) circuit comprised of the standard and a standby accessory. Components of the standard circuit include: aortic cannula, three-stage venous cannula, coated tubing, a centrifugal pump, a new-generation membrane oxygenator with integrated arterial filter, a venous air removal device, a soft coated bag and pulmonary artery as well as aortic root vent. In addition, there is a standby hard-shell reservoir in parallel to the venous line, so as to convert the closed system to an open one. The standby component is bridged to the main circuit with an afferent line which is connected just before the VARD sending blood to the hard-shell reservoir and an efferent that re-directs it back to the VARD. A cell-saver device is added to the circuit for collecting shed blood and washing red blood cells for autotransfusion.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary artery bypass grafting under conventional extracorporeal circulation
Description: A standard open CPB circuit is used, consisting of uncoated PVC tubing, a hard-shell venous reservoir, a microporous membrane oxygenator (Dideco, Mirandola, Italy) and a roller pump (Stöckert S3, Munich, Germany). The circuit contains a 40 μm arterial line blood filter (Dideco, Mirandola, Italy) and it is primed with 1500 mL of a balanced crystalloid/colloid solution (1000 mL of Ringer's solution, 200 mL of mannitol 20%, and 300 mL of hydroxyethyl starch 6%). Cardiotomy as well as sump sucker are integrated to the circuit.
Study: NCT00556894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CF101
Description: orally q12h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CF101
Description: orally q12h

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: orally q12h
Study: NCT04525612

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-BNU-PSMA
Description: Each patient receive a single intravenous injection of 68Ga-BNU-PSMA, and undergo PET/CT scan within specified time.
Study: NCT02048020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Description: Undergo IMRT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study: NCT00849966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celebrex suspension
Description: Patients will be randomized to receive celecoxib suspension 6 mg/kg one hour prior to their scheduled surgery. In addition the patient will receive seven weight-based doses of celecoxib (3 mg/kg) to be administered every 10-12 hours while the child is awake; the first dose being administered the evening of surgery.~All participants will receive undergo and post surgery anesthetic treatment according to the usual standards of practice at CHEO.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Celebrex suspension
Description: Patients will be randomized to receive celecoxib suspension 6 mg/kg one hour prior to their scheduled surgery. In addition the patient will receive seven weight-based doses of celecoxib (3 mg/kg) to be administered every 10-12 hours while the child is awake; the first dose being administered the evening of surgery.~All participants will receive undergo and post surgery anesthetic treatment according to the usual standards of practice at CHEO.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will be randomized to receive placebo by mouth one hour prior to their scheduled surgery. In addition the patient will receive seven weight-based doses of the placebo to be administered every 10-12 hours while the child is awake; the first dose being administered the evening of surgery.~All participants will receive undergo and post surgery anesthetic treatment according to the usual standards of practice at CHEO.
Study: NCT03166280

Intervention type: DRUG
Intervention: Sofosbuvir 400 mg
Description: treatment for hepatitis c by sofosbuvir (Sovaldi) 400 mg/day

Intervention type: DRUG
Intervention: Daclatasvir 60 mg/day
Description: treatment for hepatitis c by Daclatasvir 60 mg/day
Study: NCT01899599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PankoMab-GEX
Description: start dose 500mg at C0D1, maintenance dose 1700mg at CxD1, Number of Cycles: until progression or unacceptable toxicity develops.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: start dose matching 500mg at C0D1, maintenance dose matching 1700mg at CxD1, Number of Cycles: until progression or unacceptable toxicity develops.
Study: NCT02371707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idalopirdine 60 mg formulation A (test)
Description: Tablet for oral use, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idalopirdine 60 mg formulation B (reference)
Description: Tablet for oral use, single dose
Study: NCT01567969

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive In-home Child and Adolescent Psychiatric Service
Description: A six to seven month intensive intervention provided by a clinical team consisting of a master's-level clinician and a bachelor's-level mental health counselor delivering comprehensive psychiatric and case management services in the child's home. One or both members of the team works with the child and the family three times a week in the home. Delivery of direct and indirect services average 5.5 hours of service per week.
Study: NCT00690534

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Regular
Description: insulin, 0.2 mU/kg/min for 3 hours
Study: NCT01567969

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home-based Child Treatment Coordination
Description: A six to seven month home-based case management service delivered by a master's level clinician. The coordinator meets with the child's parent/legal guardian in the child's home once a month and conducts weekly phone conversations to facilitate referral and access to appropriate mental health services for the child.
Study: NCT03812965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: 2 units/point of botulinum toxin type A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: 2 units/point of botulinum toxin type A
Study: NCT02927457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2646264 1%
Description: A cream for topical application with a concentration of 1% GSK2646264.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2646264 1%
Description: A cream for topical application with a concentration of 1% GSK2646264.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2646264 1%
Description: A cream for topical application with a concentration of 1% GSK2646264.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2646264 1%
Description: A cream for topical application with a concentration of 1% GSK2646264.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2646264 1%
Description: A cream for topical application with a concentration of 1% GSK2646264.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2646264 1%
Description: A cream for topical application with a concentration of 1% GSK2646264.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive matching Placebo topically.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive matching Placebo topically.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive matching Placebo topically.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive matching Placebo topically.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive matching Placebo topically.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive matching Placebo topically.
Study: NCT03789201

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS EEG
Description: attempt to use TMS EEG to measure connectivity between cortical areas

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS fMRI
Description: compare measurements to established functional connectivity measures; e.g., EEG coherence and fMRI
Study: NCT03076424

Intervention type: OTHER
Intervention: no intervention used
Description: Patients will be giving a blood sample after 8 hours of fasting.
Study: NCT02854865

Intervention type: OTHER
Intervention: echocardiography
Description: assess whether GLPSS measured during cardiac surgery using AFI is superior to E/Ea ratio in estimation of LVFP measured as PCWP
Study: NCT01722058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peptide application
Study: NCT03076424

Intervention type: OTHER
Intervention: no intervention used
Description: Patients will be giving a blood sample after 8 hours of fasting.

Intervention type: OTHER
Intervention: no intervention used
Description: Patients will be giving a blood sample after 8 hours of fasting.
Study: NCT01782651

Intervention type: DRUG
Intervention: Lapatinib plus capecitabine
Description: Lapatinib plus capecitabine
Study: NCT02567071

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: perineal impregnated swab
Description: After planned C-section birth, newborns will suck on previously impregnated swab by perineal and vaginal mother secretions.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: clean swab
Description: After planned C-section birth, newborns will suck on clean swab.
Study: NCT00020670

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD 40
Study: NCT01942629

Intervention type: OTHER
Intervention: their will be no intervention in any of the groups, the study is retrospective

Intervention type: OTHER
Intervention: their will be no intervention in any of the groups, the study is retrospective

Intervention type: OTHER
Intervention: their will be no intervention in any of the groups, the study is retrospective
Study: NCT01465464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orantinib (TSU-68)
Description: 200 mg (1 tablet) of Orantinib was administered orally twice per day after meals, morning and evening.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet was administered orally twice per day after meals, morning and evening.
Study: NCT04603729

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 2 MG/ML
Description: Dexamethasone 8mg/day will be given intravenous for 5 days to group 1 participants

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone Injection
Description: methylprednisolone 1mg/kg/day will be given intravenous for 5 days to group 2 participants
Study: NCT02388984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Compound danshen dripping pills
Description: Dosage form:pill. Dosage:20pills. Frequency:three times per day. Duration:24 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosage form:pill. Dosage:20pills. Frequency:three times per day. Duration:24 weeks.
Study: NCT04307485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: 90mg ticargrelor based DAPT vs 60mg ticargrelor based DAPT
Study: NCT04383925

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG-Japan
Description: Infant (\<1 year) 0.05 ml dose of resuspended BCG-Japan (Tokyo strain 172, Japan BCG Laboratory, 1-5-21 Otsuka, Bunkyo-ku, Tokyo, 112-0012 Japan).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BCG-Russia
Description: Infant (\<1 year) 0.05 ml dose of resuspended BCG-Russia (Serum Institute of India)
Study: NCT01467518

Intervention type: DRUG
Group type: OTHER
Intervention: Dolutegravir
Description: Dolutegravir is an experimental drug in the integrase inhibitor class for the treatment of HIV. Dose of 50mg every 12 hours for 5 days.

Intervention type: DRUG
Group type: OTHER
Intervention: Methadone
Description: Methadone is a synthetic opioid used in the treatment of opioid dependence. Subjects will be on individualize stabe dose for 8 days.

Intervention type: DRUG
Group type: OTHER
Intervention: Methadone
Description: Methadone is a synthetic opioid used in the treatment of opioid dependence. Subjects will be on individualize stabe dose for 8 days.
Study: NCT02008487

Intervention type: OTHER
Group type: OTHER
Intervention: Wound powder application
Description: Powder application to wound per protocol.
Study: NCT04150107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORMD-0801 Treatment A
Description: Treatment A: 24 mg (16 mg capsule + 8 mg capsule) Once Daily (QD) at bedtime

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORMD-0801 Treatment A
Description: Treatment A: 24 mg (16 mg capsule + 8 mg capsule) Once Daily (QD) at bedtime

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORMD-0801 Treatment B
Description: Treatment B: 8 mg (8 mg capsule) three times a day (TID) 45-90 minutes before meals

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORMD-0801 Treatment B
Description: Treatment B: 8 mg (8 mg capsule) three times a day (TID) 45-90 minutes before meals

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Fish oil capsule
Study: NCT04417361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galcanezumab Prefilled Syringe
Description: Galcanezumab will be supplied in preloaded syringes, each with a dose of 120 mg. Participants will first receive the first month's supply (240 mg) at study visit 2, and then will receive a two month supply at study visit 3. So, at study visit 2 and 3, each participant will get two pre-filled syringes.
Study: NCT04150107

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Fish oil capsule
Study: NCT01967810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANG1005
Description: ANG1005 at a starting dose of 650 mg/m\^2 or 600 mg/m\^2 by intravenous infusion once every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANG1005
Description: ANG1005 at a starting dose of 650 mg/m\^2 or 600 mg/m\^2 by intravenous infusion once every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANG1005
Description: ANG1005 at a starting dose of 650 mg/m\^2 or 600 mg/m\^2 by intravenous infusion once every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: For participants enrolled in the bevacizumab-refractory recurrent GBM arm (Arm 2), treatments with bevacizumab may be continued and administered every 2 or 3 weeks at the Investigator's discretion.
Study: NCT03091478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200mg every 3 weeks
Study: NCT04417361

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be supplied in preloaded syringes, each with a dose of 120 mg. Participants will first receive the first month's supply (240 mg) at study visit 2, and then will receive a two month supply at study visit 3. So, at study visit 2 and 3, each participant will get two pre-filled syringes.
Study: NCT04661046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine
Description: Chinese medicine prescription
Study: NCT03593057

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual therapy
Description: Manual therapy protocol and self-care advice and body awareness.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control group
Description: Advice on self-care and body awareness.
Study: NCT04385186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inactivated convalescent plasma
Description: Day 0: Transfusion of 200mL of ABO -Rh compatible inactivated convalescent plasma, Start of support treatment selected by medical staff according to each institutional protocol~Day 1: Transfusion of 200mL of ABO -Rh compatible inactivated convalescent plasma

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Support treatment
Description: Day 0: Start of support treatment selected by medical staff according to each each institutional protocol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Support treatment
Description: Day 0: Start of support treatment selected by medical staff according to each each institutional protocol
Study: NCT02341352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluoride varnish
Description: Sodium fluoride 50mg/ml

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immunoglobulin Yolk
Description: anti-Streptococcus mutans IgY

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: 2g/day，Lactobacillus rhamnosus HN001, Bifidobacterium lactis Bi-07, Bifidobacterium lactis HN019, maltodextrin, fructose, skimmed milk powder
Study: NCT01867762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ 49095397
Description: JNJ 49095397 400 microgram will be inhaled by participants once daily by using a dry powder inhaler for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be inhaled by participants once daily by using a dry powder inhaler for 12 weeks.
Study: NCT02769832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel 100 mg/m2, day 1 and day 8 of a 21-day cycle
Study: NCT01862536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: Daily use of study drug to treat pulmonary hypertension.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Daily use in double blind study.
Study: NCT02769832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m2, day 1 and day 8 of a 21-day cycle
Study: NCT02825979

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cryoballoon-based PVI
Description: Patients randomized to first-line cryoballoon (CB) ablation will have the pulmonary vein isolation procedure performed according to standard clinical practice using the Arctic Front Cryoballoon ablation catheter. No anti-arrhythmic drugs will be prescribed in this arm.
Study: NCT03370718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Given PO
Study: NCT02825979

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-Arrhythmic Drug Therapy
Description: Antiarrhythmic drug therapy (Class I - flecainide, propafenone; Class III - sotalol, dronedarone) will prescribed and monitored based on local clinical practice, and according to guideline-suggested drug management for symptomatic patients with paroxysmal AF.
Study: NCT00718146

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Split virion, inactivated Influenza vaccine
Description: 0.5 mL, Intramuscular (IM)
Study: NCT03370718

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacogenomic Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic Study
Description: Correlative studies